BPC-157 — Research Overview
Chemical Name: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val Also Known As: Body Protection Compound-157, Gastric Pentadecapeptide, Bepecin, PL 14736, PLD-116 Molecular Weight: 1419 Da Structure: Synthetic 15 amino acid pentadecapeptide derived from a protein found in human gastric juice. Sequence has no known homology to other known peptides. Category: Gastroprotective and cytoprotective research peptide
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is BPC-157?
BPC-157 is a synthetic 15-amino acid pentadecapeptide first described in 1992 and derived from a partial sequence of body protection compound — a protein found endogenously in human gastric juice where it functions to promote mucosal integrity and gastrointestinal homeostasis. The full amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, and it has no known sequence homology to other characterized peptides, making it a structurally unique research compound.
BPC-157 was entered into clinical trials under the designation PL 14736 and Bepecin as a potential therapy for inflammatory bowel disease by Pliva, Croatia, where it was demonstrated to be safe in human subjects. That clinical safety data has informed the ongoing use of BPC-157 as a research compound across a broad range of laboratory models since the late 1990s.
What makes BPC-157 particularly notable in the research literature is its reported activity across an exceptionally wide range of tissue types and injury models at very low doses — typically in the nanogram to microgram per kilogram range — spanning the gastrointestinal tract, musculoskeletal system, peripheral nervous system, cardiovascular system, liver, and skin. A 2024 preclinical toxicity assessment found no minimum toxic dose or lethal dose in animal models, and no teratogenic, genotoxic, anaphylactic, or local toxic effects were identified at doses tested, providing a basis for the argument that formal human clinical trials are warranted.
BPC-157 is listed as a prohibited substance by the World Anti-Doping Agency under category S0 (non-approved substances) and is banned in professional sports contexts. It is not approved by the FDA for any indication.
Mechanism of Action
BPC-157 exerts its tissue-protective and healing effects through several interconnected molecular pathways that have been characterized across preclinical research. The primary mechanisms identified in published literature are as follows.
VEGFR2 activation and angiogenesis: BPC-157 activates vascular endothelial growth factor receptor 2 (VEGFR2) on endothelial cells, triggering phosphorylation events that initiate the Akt-eNOS signaling axis. This cascade increases nitric oxide production in blood vessel walls, promoting vasodilation and the formation of new blood vessels at sites of tissue injury. Angiogenesis — the growth of new capillaries — is a prerequisite for effective tissue repair, as damaged tissue requires restored blood supply for oxygen and nutrient delivery.
Nitric oxide system modulation: BPC-157 has a complex relationship with the nitric oxide system. Published research describes it as both maintaining the protective functions of nitric oxide while counteracting its cytotoxic and damaging actions in injured tissues. This dual modulation of the NO system is proposed as a central mechanism underlying BPC-157’s cytoprotective effects across multiple organ systems.
FAK-paxillin pathway activation: BPC-157 promotes the phosphorylation of focal adhesion kinase (FAK) and paxillin in a dose-dependent manner. These proteins regulate cell migration and adhesion to the extracellular matrix — processes essential for wound healing because repair cells must migrate into damaged tissue and anchor themselves to begin rebuilding.
ERK1/2 signaling activation: The extracellular signal-regulated kinase 1 and 2 pathway is activated by BPC-157, driving downstream targets including c-Fos, c-Jun, and Early Growth Response gene 1 (Egr-1). Egr-1 functions as a transcriptional master switch that upregulates genes involved in cell growth, survival, and vascular formation.
Growth hormone receptor upregulation: BPC-157 dose- and time-dependently increases the expression of growth hormone receptor in tendon fibroblasts at both mRNA and protein levels. This sensitizes local tissue to growth hormone signaling, potentially amplifying the anabolic and repair-promoting effects of endogenous growth hormone at injury sites without elevating systemic growth hormone levels.
Collateral blood vessel activation: Research from the primary BPC-157 research group at the University of Zagreb describes a prompt activation of collateral blood vessel pathways by BPC-157, effectively bypassing occluded or damaged vessels and restoring blood flow to ischemic tissues rapidly.
Published Research
Study 1 — Tendon Healing: FAK-Paxillin Pathway and Fibroblast Migration
Authors: Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH Year: 2011 Journal: Journal of Orthopaedic Research PMID: 21030672 Full text: https://pubmed.ncbi.nlm.nih.gov/21030672/
This study examined the cellular mechanisms by which BPC-157 enhances tendon healing, using cultured tendon fibroblasts derived from rat Achilles tendon. The researchers characterized three key cellular behaviors: outgrowth from tendon explants, cell survival under stress, and cell migration.
BPC-157 significantly accelerated the outgrowth of tendon fibroblasts from tendon explants in culture, suggesting enhanced regenerative activity at the tissue level.
BPC-157 markedly increased in vitro migration of tendon fibroblasts in a dose-dependent manner as measured by transwell filter migration assay, and accelerated the spreading of cells on culture dishes.
F-actin formation was induced in BPC-157-treated fibroblasts, indicating active cytoskeletal reorganization consistent with a migratory and adhesive cellular phenotype.
Phosphorylation levels of both FAK and paxillin were dose-dependently increased by BPC-157 while total protein amounts were unchanged, confirming that BPC-157 activates rather than upregulates these signaling proteins.
The authors concluded that BPC-157 promotes tendon explant outgrowth, cell survival under stress, and tendon fibroblast migration through activation of the FAK-paxillin pathway, providing a mechanistic basis for its observed tendon healing effects in animal models.
Study 2 — Growth Hormone Receptor Upregulation in Tendon Fibroblasts
Authors: Chang CH, Tsai WC, Hsu YH, Pang JH Year: 2014 Journal: Molecules PMCID: PMC6271067 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/
This study used cDNA microarray analysis to identify the most abundantly upregulated genes in tendon fibroblasts following BPC-157 treatment, and then characterized the growth hormone receptor finding in detail.
Growth hormone receptor was identified as one of the most abundantly upregulated genes in tendon fibroblasts treated with BPC-157 in cDNA microarray screening.
BPC-157 dose- and time-dependently increased growth hormone receptor expression at both the mRNA and protein levels as measured by RT-PCR and Western blot analysis.
When growth hormone was added to BPC-157-treated tendon fibroblasts, cell proliferation increased dose- and time-dependently, demonstrating that the BPC-157-induced receptor upregulation is functionally significant — it primes local tissue to respond more robustly to growth hormone stimulation.
The authors proposed that BPC-157 may play an important role in promoting tendon healing by sensitizing tendon fibroblasts to growth hormone, potentially reducing the amount of growth hormone required for effective local tissue repair.
Study 3 — Wound Healing: Angiogenesis and ERK1/2 Signaling in Alkali Burn Model
Authors: Xue XC et al. Year: 2015 Journal: Drug Design, Development and Therapy (PubMed) PMID: 25995620 Full text: https://pubmed.ncbi.nlm.nih.gov/25995620/
This study investigated BPC-157’s effects on wound healing in a rat alkali burn model — a clinically relevant injury type known for tissue penetration and poor healing outcomes. BPC-157 was applied topically at concentrations of 200, 400, and 800 ng/mL and outcomes were compared to basic fibroblast growth factor treatment and untreated controls.
Topical BPC-157 significantly accelerated wound closure following alkali burns compared to untreated controls.
Histological analysis showed better granulation tissue formation, reepithelialization, dermal remodeling, and higher collagen deposition in BPC-157-treated wounds compared to controls.
BPC-157 promoted VEGF-a expression in wounded skin tissue at both protein and mRNA levels, confirming pro-angiogenic signaling in wound tissue.
BPC-157 significantly enhanced proliferation and migration of human umbilical vein endothelial cells in vitro and accelerated vascular tube formation.
ERK1/2 phosphorylation and its downstream targets c-Fos, c-Jun, and Egr-1 were upregulated by BPC-157, identifying the ERK1/2 signaling pathway as a key mediator of its wound-healing effects.
Study 4 — Inflammatory Bowel Disease and Gastrointestinal Healing: Clinical Trial Safety Context
Authors: Klicek R, Sever M, Radic B, Drmic D et al. Year: 2008 Journal: Journal of Pharmacological Sciences PMID: 18818478 Full text: https://pubmed.ncbi.nlm.nih.gov/18818478/
This study examined BPC-157’s effects on persistent colocutaneous fistula in rats — a severe gastrointestinal injury model — and placed it in the context of BPC-157’s established safety record in human clinical trials for inflammatory bowel disease. The study used BPC-157 at doses of 10 micrograms per kilogram and 10 nanograms per kilogram.
BPC-157 significantly accelerated healing of colocutaneous fistulas across all measured timepoints compared to controls, whether administered in drinking water or by intraperitoneal injection.
The authors noted that BPC-157, under the trial designation PL14736, had been demonstrated to be safe in human clinical trials for inflammatory bowel disease and safe for intestinal anastomosis therapy — providing important human safety context for the ongoing preclinical research program.
The study characterized the nitric oxide system’s involvement in BPC-157’s gastrointestinal healing effects, consistent with the broader mechanistic literature on BPC-157 and nitric oxide modulation.
Study 5 — Systematic Review: Orthopaedic Sports Medicine Applications
Authors: Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM Year: 2025 Journal: Sports Health (PubMed and PMC) PMID: 40756949 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/
This 2025 systematic review conducted in accordance with PRISMA guidelines searched PubMed, Cochrane, and Embase from database inception through June 2024, evaluating 36 studies on BPC-157 from an orthopedic sports medicine perspective. It represents the most comprehensive and recently published synthesis of the musculoskeletal BPC-157 literature available.
BPC-157 has improved outcomes in muscle, tendon, ligament, and bone injury models across animal studies, promoting healing through boosted growth factors and reduced inflammation.
In one human case series within the reviewed literature, 7 out of 12 people with chronic knee pain reported relief lasting over six months after receiving a single intra-articular BPC-157 injection.
BPC-157 is metabolized in the liver with a plasma half-life of less than 30 minutes and is cleared by the kidneys.
Preclinical safety studies showed no adverse effects across multiple organ systems. No clinical safety data in humans have been formally published beyond the inflammatory bowel disease trial context.
The authors concluded that BPC-157 shows promise for promoting recovery from musculoskeletal injuries but noted that adverse effects are possible due to unregulated manufacturing and the absence of formal human clinical safety data, and recommended that formal clinical trials be initiated.
Important Note on the Research Landscape
Researchers and clinicians reviewing the BPC-157 literature should be aware that as of a May 2025 PubMed search, over 80% of published BPC-157 studies list researchers from a single group at the University of Zagreb, primarily under the authorship of Professor Predrag Sikiric, as the primary or senior authors. Independent laboratory replications of BPC-157 findings are limited in number. This concentration of research output from a single group is noted in recent published peer-reviewed commentary in Pharmaceuticals (2025) and represents a genuine limitation on the generalizability of the existing literature. Published studies also predominantly use only two dose levels — 10 micrograms per kilogram and 10 nanograms per kilogram — meaning dose-response relationships at higher or repeated exposures and long-term safety profiles are not well characterized in the existing literature.
Additionally because BPC-157 promotes angiogenesis through VEGFR2 and Akt-eNOS signaling, theoretical concerns about potential interaction with tumor growth in oncology contexts have been raised in published commentary and remain an open question that requires formal investigation. No published in vivo studies have demonstrated that BPC-157 inhibits or promotes solid tumor progression.
These considerations are included here in the interest of scientific accuracy. They do not negate the substantial body of preclinical evidence but are important context for any researcher designing protocols using this compound.
Current Research Status
BPC-157 was entered into human clinical trials as a therapy for inflammatory bowel disease under the designation PL 14736 and Bepecin, where it was demonstrated to be safe in human subjects. A registered clinical trial under the Bepecin designation was noted in 2015 but did not result in any regulatory approvals. BPC-157 is not approved by the FDA for any indication.
BPC-157 is listed on the WADA 2022 Prohibited Substances List under category S0 (non-approved substances), prohibiting its use in competitive sport contexts.
The following remain to be established through formal human clinical research:
Efficacy and safety in human populations across the injury and disease models studied preclinically.
Dose-response relationships in humans across the full therapeutic range.
Long-term safety profile with repeated or prolonged administration.
Interaction with oncological processes in human subjects given the pro-angiogenic mechanism.
Pharmacokinetics and bioavailability in humans across different routes of administration.
Reconstitution Note
BPC-157 is a peptide compound. Bacteriostatic water is the standard and preferred reconstitution solvent for BPC-157 in laboratory research settings. BPC-157 is water-soluble and dissolves readily in bacteriostatic water without requiring acidic solvents. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the BPC-157 product page: https://roguecompounds.com/product/bpc-157/